Use your antibodies-online credentials, if available.
May have a role in the regulation of spermatogenesis.. 再加上，我们可以发PD-1 蛋白 (93) 和 PD-1 试剂盒 (24)和数多这个蛋白质的别的产品。
Showing 10 out of 655 products:
Human Polyclonal PD-1 Primary Antibody for BR, CyTOF - ABIN5012979
Wan, Nie, Liu, Feng, He, Xu, Zhang, Dong, Zhang: Aberrant regulation of synovial T cell activation by soluble costimulatory molecules in rheumatoid arthritis. in Journal of immunology (Baltimore, Md. : 1950) 2007
Show all 11 Pubmed References
Human Polyclonal PD-1 Primary Antibody for ELISA (Detection), FACS - ABIN4899871
Sakthivel, Ramanujam, Wang, Pirskanen, Lefvert: Programmed Death-1: from gene to protein in autoimmune human myasthenia gravis. in Journal of neuroimmunology 2008
Show all 9 Pubmed References
Human Monoclonal PD-1 Primary Antibody for BR, FACS - ABIN2689142
Bennett, Luxenberg, Ling, Wang, Marquette, Lowe, Khan, Veldman, Jacobs, Valge-Archer, Collins, Carreno: Program death-1 engagement upon TCR activation has distinct effects on costimulation and cytokine-driven proliferation: attenuation of ICOS, IL-4, and IL-21, but not CD28, IL-7, and IL-15 responses. in Journal of immunology (Baltimore, Md. : 1950) 2003
Show all 8 Pubmed References
Mouse (Murine) Monoclonal PD-1 Primary Antibody for BR, FACS - ABIN2689141
Nishimura, Agata, Kawasaki, Sato, Imamura, Minato, Yagita, Nakano, Honjo: Developmentally regulated expression of the PD-1 protein on the surface of double-negative (CD4-CD8-) thymocytes. in International immunology 1997
Show all 7 Pubmed References
Human Polyclonal PD-1 Primary Antibody for IHC, ELISA - ABIN1002980
Holling, Schooten, van Den Elsen: Function and regulation of MHC class II molecules in T-lymphocytes: of mice and men. in Human immunology 2004
Show all 4 Pubmed References
Human Polyclonal PD-1 Primary Antibody for IHC, ELISA - ABIN1002981
Ishida, Agata, Shibahara, Honjo: Induced expression of PD-1, a novel member of the immunoglobulin gene superfamily, upon programmed cell death. in The EMBO journal 1992
Show all 4 Pubmed References
Human Monoclonal PD-1 Primary Antibody for ICC, FACS - ABIN438813
Dorrell, Abraham, Lanxon-Cookson, Canaday, Streeter, Grompe: Isolation of major pancreatic cell types and long-term culture-initiating cells using novel human surface markers. in Stem cell research 2009
Show all 3 Pubmed References
Mouse (Murine) Polyclonal PD-1 Primary Antibody for CyTOF, FACS - ABIN4899873
Kasagi, Kawano, Okazaki, Honjo, Morinobu, Hatachi, Shimatani, Tanaka, Minato, Kumagai: Anti-programmed cell death 1 antibody reduces CD4+PD-1+ T cells and relieves the lupus-like nephritis of NZB/W F1 mice. in Journal of immunology (Baltimore, Md. : 1950) 2010
Show all 3 Pubmed References
Human Polyclonal PD-1 Primary Antibody for IF (p), IHC (p) - ABIN735608
Zhang, Niyazi, Hong, Tuluwengjiang, Zhang, Zhang, Su, Bao: Effect of EBI3 on radiation-induced immunosuppression of cervical cancer HeLa cells by regulating Treg cells through PD-1/PD-L1 pathway. in Tumour biology 2017
Show all 2 Pubmed References
Human Monoclonal PD-1 Primary Antibody for FACS - ABIN2479653
Ochonisky, Chosidow, Kuentz, Man, Fraitag, Pelisse, Revuz: Cogan's syndrome. An unusual etiology of urticarial vasculitis. in Dermatologica 1992
Show all 3 Pubmed References
Early phase clinical trials using PD-1 or PD-L1 (显示 CD274 抗体) inhibitors alone or in combination have shown objective tumor responses and durable long-term disease control, in heavily pre-treated patients, notably in the TN subtype. Blockade of PD-1 or PD-L1 (显示 CD274 抗体) shows impressive antitumor activity in some subsets of breast cancer patients
Differential expression of immunological markers relating to the PD-1/PD-L1 (显示 CD274 抗体) pathway in blood can be used as potential diagnostic and prognostic markers in ovarian cancers. These data have implications for the development and trial of anti-PD-1/PD-L1 (显示 CD274 抗体) therapy in ovarian cancer.
LAG-3 (显示 LAG3 抗体)+ iTILs are enriched in estrogen receptor (显示 ESR1 抗体)-negative breast cancers and represent an independent favorable prognostic factor. In addition, a high proportion of PD-1/PD-L1 (显示 CD274 抗体)+ tumors are co-infiltrated with LAG-3 (显示 LAG3 抗体)+ TILs.
An IDO1 (显示 IDO1 抗体) inhibitor, epacadostat also demonstrated promising activity in combination with the PD-1 checkpoint inhibitors in other solid tumors, including melanoma, urothelial carcinoma, renal cell carcinoma (显示 MOK 抗体), and non-small cell lung cancer
PD-L1 (显示 CD274 抗体) was positive in tumor cells in 2/13 cases, weak positive in 7/13, and negative in 4/13 cases, respectively
we report the first case of immune microenvironment profiling and response to anti-PD-1 in a patient with Renal medullary carcinoma to our knowledge. This case suggests that anti-PD-1 based therapies may have clinical activity in Renal medullary carcinoma
We present two cases of metastatic melanoma treated with nivolumab and pembrolizumab (anti PD-1). Both patients developed acute interstitial nephritis during immune checkpoint therapy
the positive rate of PD-L2 (显示 PDCD1LG2 抗体) did not show any differences between primary tumors and metastatic lymph nodes. In multivariate analysis, PD-L1 (显示 CD274 抗体) expression, PD-L2 (显示 PDCD1LG2 抗体) expression, a low density of CD8 (显示 CD8A 抗体)(+) T cells in primary tumors, and PD-1 expression on CD8 (显示 CD8A 抗体)(+) T cells in primary tumors were associated with poor prognosis.
Relative to controls, the expression of PD-1 and PD-L1 (显示 CD274 抗体) on peripheral blood and tumor infiltrating T cells increased with disease progression. Upregulation of expression promotes t-cells apoptosis in gastric adenocarcinoma.
These data support the combinatorial approach of in situ suppression of the PD-L inhibitory checkpoints with DC-mediated IL15 (显示 IL15 抗体) transpresentation to promote antigen-specific T-cell responses and, ultimately, contribute to graft-versus-tumor immunity
Anti-PD-1/PD-L1 (显示 CD274 抗体) therapy inhibited CMT167 orthotopic lung tumors by 95%. .Silencing PD-L1 (显示 CD274 抗体) expression in CMT167 cells resulted in smaller orthotopic tumors that remained sensitive to anti-PD-L1 (显示 CD274 抗体) therapy, whereas implantation of CMT167 cells into PD-L1 (显示 CD274 抗体)(-) mice blocked orthotopic tumor growth, indicating a role for PD-L1 (显示 CD274 抗体) in both the cancer cell and the microenvironment.
Combination therapies that depend on checkpoint inhibitor antibodies (Abs) such as for PD-1 or its ligand (PD-L1 (显示 CD274 抗体)) together with immune stimulatory agonist Abs like anti-OX40 (显示 TNFRSF4 抗体) are being tested in the clinic to achieve improved antitumor effects
Inhibition of Fut8 (显示 FUT8 抗体), a core fucosyltransferase, by genetic ablation or pharmacologic inhibition reduced cell-surface expression of PD-1 and enhanced T cell activation, leading to more efficient tumor eradication.
An examination of the mechanisms of immunity behind this long-term protection in PD-1 knockout mice showed a key role for parasite-specific CD8 (显示 CD8A 抗体)(+) T cells even when CD4 (显示 CD4 抗体)(+) T cells and B cells responded to re-infection.
To test the in vivo activity of REGN2810, which does not cross-react with murine PD-1, knock-in mice were generated to express a hybrid protein containing the extracellular domain of human PD-1, and transmembrane and intracellular domains of mouse PD-1
The combination of tumor vaccination to induce high avidity tumor specific T cell responses and PD-1 blockade synergises to provide tumor therapy and 85% survival in the aggressive B16 melanoma model.
Blockade of PD-1 with monoclonal antibody may be an effective treatment during the postoperative period for restoring surgery-induced immunosuppression.
Data suggest that genetic or environmental factors that even moderately affect the expression of both PD-1 and FoxP3 (显示 FOXP3 抗体) can cause life-threatening autoimmune diseases by disrupting the T-cell homeostasis.
Data (including data from studies in transgenic/knockout mice) suggest that T-cell expression of Mirn155 is required to limit melanoma growth; miR (显示 MLXIP 抗体)-155, Pdcd1, Pdcd1l1 (显示 CD274 抗体), and Ctla4 (显示 CTLA4 抗体) appear to regulate overlapping pathways promoting antitumor immunity. [Mirn155 = microRNA 155; Pdcd1 = programmed cell death 1 protein; Pdcd1l1 (显示 CD274 抗体) = programmed cell death 1 ligand 1 (显示 CD274 抗体) protein; Ctla4 (显示 CTLA4 抗体) = cytotoxic T-lymphocyte-associated protein 4 (显示 CTLA4 抗体)]
PD-1 plays a vital role in brain inflammation via regulation of Fgl-2 (显示 FGL2 抗体) after ICH (显示 ACE 抗体), and that manipulation of PD-1 might be a promising therapeutical target in ICH (显示 ACE 抗体).
Data show that CTLA-4 (显示 CTLA4 抗体)(+)PD-1(-) memory CD4 (显示 CD4 抗体)(+) T cells, which share phenotypic markers with regulatory T cells, were enriched in SIV DNA in blood, lymph nodes (LN), spleen, and gut (显示 GUSB 抗体), and contained replication-competent and infectious virus.
Compared to before immunosuppression, PD-1 expression increased at reactivation. Increased T cells before zoster is likely due to virus reactivation.
A PD-1(high) phenotype is associated with accelerated in vivo CD8 (显示 CD8A 抗体) T cell turnover in SIV-infections, especially within the SIV-specific CD8 (显示 CD8A 抗体) T cell pool.
High levels of PD-1 expression on CD4 (显示 CD4 抗体)(+) T cells in lymph nodes of rhesus macaques can serve as a valuable marker to identify T follicular helper cells.
Data indicate that PD-1 expression is increased as a result of T cell activation during a primary immune response as well as during persistent immune activation in macaques.
PD-1 can serve as a sensitive indicator of persistent, low-level virus replication
This gene encodes a cell surface membrane protein of the immunoglobulin superfamily. This protein is expressed in pro-B-cells and is thought to play a role in their differentiation. In mice, expression of this gene is induced in the thymus when anti-CD3 antibodies are injected and large numbers of thymocytes undergo apoptosis. Mice deficient for this gene bred on a BALB/c background developed dilated cardiomyopathy and died from congestive heart failure. These studies suggest that this gene product may also be important in T cell function and contribute to the prevention of autoimmune diseases.
programmed cell death protein 1
, protein PD-1
, programmed cell death 1
, programmed death 1